Type 1 Diabetes Mellitus Clinical Trial
Official title:
A Randomised Trial Investigating Pharmacokinetic Properties of Ultra-Rapid-Acting Insulin Lispro (URAL) in Subjects With Type 1 Diabetes Mellitus
NCT number | NCT02206568 |
Other study ID # | PER511 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | September 2014 |
Verified date | May 2015 |
Source | AMAG Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Signed informed consent 2. Male subjects age 18-65 years inclusive 3. Type 1 diabetes mellitus diagnosed clinically >= 12 months 4. Treatment with multiple daily insulin injections or CSII >= 12 months 5. Current total daily insulin treatment <1.2 (I)U/kg/day 6. Current total daily bolus insulin treatment <0.7 (I)U/kg/day 7. Body mass index 18.0-30.0 kg/m2 inclusive 8. HbA1c =<9.0% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive) 9. C-peptide =< 0.30 nmol/L Exclusion Criteria: 1. Known or suspected hypersensitivity to trial products or related products 2. Previous participation in this trial. . 3. Receipt of any non-marketed investigational product within 3 months 4. Clinically significant abnormal haematology, biochemistry, liver enzymes, or coagulation screening tests 5. Suffer from or history of a life threatening disease or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal , neurological, psychiatric diseases or other major disorders 6. History of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in 1st degree relatives 7. Cardiac problems defined as decompensated heart failure (New York Heart Association class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time. 8. Supine blood pressure at screening outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic . Pulse outside 50 to 90 bpm. 9. Clinically significant abnormal ECG at screening. 10. Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy. 11. Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety. 12. Subject positive for HBs-Ag, HCV-Ab 13. Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies, or HIV-1 antigen according to locally used diagnostic testing. 14. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction. 15. Subject who has donated blood or plasma in the past month or more than 500 mL within 3 months. 16. Surgery or trauma with significant blood loss (more than 500 mL) within 3 months. 17. Current treatment with systemic (oral, IV, or inhaled) corticosteroids, monoamine oxidase inhibitors, NSAID, prostaglandin blockers, systemic non-selective beta-blockers, growth hormone (last 3 months), non-routine vitamins or herbal products (last 2 weeks). Thyroid hormones are not allowed unless the use of these has been stable during the last 3 months. Routine vitamins are permitted up to 48 hours prior to dosing. 18. Significant history of alcoholism and/or drug/chemical abuse as per Investigator's judgement or a positive result in the urine drug/alcohol breath test screen at the screening visit. 19. Heavy smoker 20. Not able or willing to refrain from smoking and use of nicotine. 21. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemia event during the last 12 months) or hypoglycaemic unawareness. 22. Subject with mental incapacity or language barriers precluding adequate understanding. 23. Potentially non-compliant or uncooperative during the trial. 24. Any condition that would interfere with trial participation or evaluation of results. 25. No relevant lipodystrophy within the area of drug administration and Doppler sonography. |
Country | Name | City | State |
---|---|---|---|
Germany | Profil Institut fur Stoffwechselforschung GmbH | Neuss |
Lead Sponsor | Collaborator |
---|---|
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Profil Institut für Stoffwechselforschung GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics of URAL | Area under the serum insulin lispro concentration-time curve from 0-30 minutes after administration | 1 day | |
Secondary | Onset of appearance of serum insulin lispro | Measurement of time to reach insulin lispro concentration >30 pmol/L in the serum | 1 day | |
Secondary | Number of subjects with adverse events | Assessment of safety and tolerability of URAL | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A |